TLX101-Px MAA Filed in Europe for Brain Cancer Imaging
MELBOURNE, AUSTRALIA & INDIANAPOLIS, UNITED STATES — February 18, 2026 Telix Pharmaceuticals has submitted a European Marketing Authorization Application...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MELBOURNE, AUSTRALIA & INDIANAPOLIS, UNITED STATES — February 18, 2026 Telix Pharmaceuticals has submitted a European Marketing Authorization Application...
MELBOURNE, Australia; INDIANAPOLIS, United States — December 22, 2025 — Telix Pharmaceuticals Limited has reported a major precision medicine...
Louvain-La-Neuve, Belgium, December 19, 2025 — IBA (Ion Beam Applications S.A.), a global leader in particle accelerator technology and...
Los Angeles, California – November 3, 2025 NeuroSigma, Inc., a Los Angeles-based bioelectronics company, has announced a groundbreaking publication...
